Peter Dull - Concepedia

Author

Peter Dull

Also Known As

, , ,, Hydroxychloroquine COVID-19 Postexposure Prophylaxis Study Team, P Dull, P M Dull, P. Dull, P.M. Dull, PETER M. DULL, Peter Dull, Peter M Dull, Peter M. Dull

115

Publications

7.3K

Citations

H-Index

Concepts

All Affiliations

Novartis (United States)Novartis (Italy)University of Oxford Ohio Pediatric Research Association Kaiser Permanente

About

Peter Dull is an author at Novartis (United States) specializing in medicine, vaccination, and infection control.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	26	31	3K
2	Public Health	5	5	554
3	Engineering	1	1	58
4	Health Sciences	1	1	65
5	Allergy	1	1	31

Peter Dull

Publications

6.2K

Citations

H-Index

Page 1

	Year	Citations
Evidence for antibody as a protective correlate for COVID-19 vaccines Kristen Earle, Donna M. Ambrosino, Andrew Fioré-Gartland, Vaccine	2021	961
Immunogenicity and Tolerability of Recombinant Serogroup B Meningococcal Vaccine Administered With or Without Routine Infant Vaccinations According to Different Immunization Schedules Nicoletta Gossger, Matthew D. Snape, Ly‐Mee Yu, JAMA ImmunologyVaccine HesitancyEffective VaccineReverse VaccinologyVaccine Target	2012	277
Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial Robert C. Read, David Baxter, David Chadwick, The Lancet VaccinationVaccine SafetyVaccine EfficacyInfection ControlBacterial Meningitis	2014	276
Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials Timo Vesikari, Susanna Esposito, Roman Prymula, The Lancet VaccinologyVaccine SafetyVaccinationReverse VaccinologyMedicine	2013	271
Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study Marı́a Elena Santolaya, Miguel L. O’Ryan, María Teresa Valenzuela, The Lancet VaccinationVaccine SafetyHealthy AdolescentsPhase 2B/3Placebo-controlled Study	2012	262
Immunogenicity of a Tetravalent Meningococcal Glycoconjugate Vaccine in Infants Matthew D. Snape, Kirsten P. Perrett, Karen Ford, JAMA	2008	215
Specific, Sensitive, and Quantitative Enzyme-Linked Immunosorbent Assay for Human Immunoglobulin G Antibodies to Anthrax Toxin Protective Antigen Conrad P. Quinn, Vera Semenova, Cheryl M. Elie, Emerging infectious diseases	2002	205
THE ETIOLOGY OF FEBRILE ILLNESS IN ADULTS PRESENTING TO PATAN HOSPITAL IN KATHMANDU, NEPAL David Murdoch, Christopher W. Woods, Mark Zimmerman, American Journal of Tropical Medicine and Hygiene Typhoid FeverHealthcare-associated InfectionGeneral HospitalPutative PathogensPathogen Characterization	2004	205
Towards a population-based threshold of protection for COVID-19 vaccines David Goldblatt, Andrew Fioré-Gartland, Marina Johnson, Vaccine VaccinationVaccine SafetyProtective ThresholdVaccine DevelopmentId50 Neutralization	2021	178
Safety and immunogenicity of an investigational maternal trivalent group B streptococcus vaccine in healthy women and their infants: a randomised phase 1b/2 trial Shabir A. Madhi, Clare Cutland, Lisa Jose, The Lancet Infectious Diseases VaccinationVaccine SafetyMaternal ImmunizationRandomised Phase 1B/2Vaccine Testing	2016	161

Page 1